Airsculpt Technologies, Inc. (AIRS) · Nov 6, 2026 · Earnings
Miss — Revenue $31.94M vs ~$34.33M consensus
AirSculpt earnings missed expectations as cases dropped 9.6%, margins collapsed, and management cut 2026 guidance despite refinancing its debt.
AirSculpt is trying to stabilize its premium body-contouring centers while expanding into GLP-1-related procedures, after Q2 showed roughly stable same-center demand and management had guided to 2026 revenue of approximately $151–157 million and adjusted EBITDA of $12–14 million. The quarter broke that stabilization story. Revenue fell 8.7% year over year to $31.9 million, well below the published consensus of roughly $34.3 million, while cases dropped 9.6% even though revenue per case rose 2.3% (Other Data; Same-center Information). The company itself says the results were “below expectations,” and it reduced full-year guidance to reflect the weakness continuing through year-end. 〔0〕
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Revenue (Income Statement) | $31.944M (-8.7%) | $34.993M | $34.33M |
| Diluted EPS (Income Statement) | $(0.10) | $(0.15) | $(0.03) |
| Cases (Other Data) | 2,483 (-10.7%) | 2,780 | |
| Adjusted EBITDA (Other Data) | $0.393M (-87.1%) | $3.039M | |
| Adjusted EBITDA margin (Other Data) | 1.2% | 8.7% |
The problem is volume, not pricing. Revenue per case increased to $12,865, but that higher ticket could not offset fewer procedures; same-center cases were down 9.6%, and adjusted EBITDA fell to just $0.4 million from $3.0 million. That makes the GLP-1 opportunity a strategy still in rollout—not yet a demonstrated offset to weakening core demand. The filing says AirSculpt is expanding GLP-1-related procedures, but provides no quantified contribution from them. 〔1〕
The refinancing buys time, but does not repair execution. AirSculpt replaced its existing credit facility with a $39.0 million term loan maturing November 5, 2031 and retained a $5.0 million undrawn revolver, reducing near-term maturity pressure. 〔2〕 But the company also raised $7.2 million through its at-the-market offering during the quarter, so liquidity improvement came alongside additional equity issuance; operating cash flow was negative $3.5 million in Q3 (Cash Flow Data).
Bottom line: This is a clear setback to AirSculpt’s stabilization story: demand weakened sharply, profitability nearly disappeared, and guidance was cut. The longer-dated refinancing limits immediate balance-sheet pressure, but the business now needs to prove that the GLP-1 expansion can reverse falling procedure volumes—not merely broaden the offering.
Q4 results and updated 2026 guidance
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!